Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions: update 2014

e17596 Background: Patients with acquired (secondary) immunodeficiencies (SID) carry an increased risk of recurrent, life-threatening infections. Methods: “Assessment of Immunoglobulins in a long-term non-interventional study” (SIGNS, ClinicalTrials.Gov is NCT01287689) is an ongoing prospective observational monitored study that, among others, documents in six-monthly intervals patients with SID who receive IG substitution therapy. Results: As of 19 January 2014, 299 patients (of a total of 616 in the database) had SID. 52% were males, mean age was 64.2 ±13.9 years. 125 (42%) patients had CLL, 77 (26%) indolent lymphoma, 42 (14%) multiple myeloma, and 54 (18%) another condition such as HIV infection (2.3%), non-Hodgkin lymphoma (6%) or a post-transplant condition (2.3%). Mean disease duration since diagnosis was 5.0 ±5.1 years. 123 patients (42%) had received chemotherapy or immunotherapy in the past 12 months, the majority in combination with rituximab (29%). 165 patients (56%) were newly treated with IG...